BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dune Medical Devices Ltd. is Relocating to Boston


1/15/2013 8:17:17 AM

BOSTON, Jan. 15, 2013 /PRNewswire/ -- Dune Medical Devices, Inc. announced today the Company has opened a new headquarters office at 25 Thomson Place, which is part of the growing Innovation District on the South Boston Waterfront. The relocation follows the recent Federal Drug Administration (FDA) approval of its flagship product, the MarginProbe¬ģ System, a breakthrough intra-operative tissue assessment device for early-stage breast cancer surgery.

"The FDA approval of MarginProbe in the U.S. is a major milestone for Dune, and an opportune time to upgrade our facilities in anticipation of robust growth in 2013. The Innovation District was an attractive location due to its reputation as a mecca for emerging medical technology in the Boston area," said Dan Levangie, chief executive officer of Dune Medical Devices.

The new headquarters will accommodate the expansion of several departments throughout 2013, including operations, sales & marketing and clinical & regulatory, to support the commercialization of MarginProbe in the U.S. and ongoing exploration of the technology's potential applications.

MarginProbe has been available in Europe since 2008 and is now available in select locations throughout the U.S., with national availability expected in early 2013. For more information, please visit www.dunemedical.com.

About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.

Dune Medical Devices is a privately held company financed by Apax Partners since 2004. It has offices in the U.S., Israel, Germany and Switzerland.

Media Contact:
Michael Graffeo
Dune Medical Devices
Michael.graffeo@dunemedical.com
(508) 620-2782

Kimberly Muscara
The Ruth Group
kmuscara@theruthgroup.com
(646) 536-7011

SOURCE Dune Medical Devices, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES